-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Galmed Pharmaceuticals Ltd. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2021 to 2023.
- Galmed Pharmaceuticals Ltd. Earnings Per Share, Diluted for the quarter ending June 30, 2024 was 0.18 USD/shares, a 81.1% decline year-over-year.
- Galmed Pharmaceuticals Ltd. annual Earnings Per Share, Diluted for 2023 was 2.5 USD/shares, a 76.5% decline from 2022.
- Galmed Pharmaceuticals Ltd. annual Earnings Per Share, Diluted for 2022 was 10.7 USD/shares, a 46.2% decline from 2021.
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)